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Abstract: It has been over 25 years since the ﬁ  rst diagnosis of what would be known as AIDS. 
Although great strides in anti-HIV therapeutics have been made, there is still a great need 
for antiretrovirals that are effective against drug-resistant HIV. Enfuvirtide (ENF) is the ﬁ  rst 
of a new class of fusion inhibitors to be approved by the US Food and Drug Administration 
for use in combination with other antiretroviral agents among HIV-1 infected patients with 
previous treatment experience. The inclusion of enfuvirtide in an optimized antiretroviral 
background regimen for the treatment of HIV-1 infected (treatment-experienced) patients 
followed the success of two critical clinical trials (TORO: T20 vs Optimized Regimen Only 
I and II). Even though injection-site reactions persisted in these trials, improved virological 
and immunological responses were observed among patients. Challenges associated with 
ENF treatment include the high cost of the drug, injection-site reactions, determining 
the optimal time to initiate treatment, and the potential for the selection of drug resistant 
mutants and viral evolution. ENF is a promising novel treatment for HIV infected individu-
als whose choices for effective treatment are limited by previous treatment and resistance. 
Understanding the implications of viral ﬁ  tness and evolution in the presence of ENF treat-
ment is crucial in determining effective and safe treatment regimens, particularly among 
treatment-experienced patients.
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Introduction
It has been over 25 years since what would be known as AIDS was ﬁ  rst recognized 
(Gottlieb et al 1981; Gottlieb 2006). Since then, antiretroviral therapy has greatly 
increased the lifespan of patients infected with HIV-1. However, drug resistance 
readily emerges during treatment, and new classes of drugs are needed to combat 
the virus. Enfuvirtide (also known as Fuzeon® or T-20; Roche) is the ﬁ  rst of a novel 
class of antiretrovirals called fusion inhibitors to receive approval for clinical use. 
Enfuvirtide (ENF) is a 36 amino-acid synthetic peptide that mimics the amino 
acids 127–162 present in heptad repeat-2 (HR-2) found in the HIV gp41 envelope 
glycoprotein subunit (Wild et al 1994; Chen et al 2002). ENF binds to residues in 
HR-1, blocking a conformational change in gp41 required for fusion of the lipid 
envelope of HIV with the cytoplasmic membrane of CD4 T cells, thus preventing 
viral entry (Chen et al 1995; Moore and Doms 2003). ENF was approved in 2003 
for use in patients who are treatment-experienced and have advanced HIV-1 infec-
tion (Fletcher 2003; Matthews et al 2004) adding a much-needed fourth class of 
drugs to treat HIV infection.
In the current review we will detail the results from ENF clinical trials. We will 
then review the clinical management of ENF based regimens including dosing, clinical 
usage, resistance and cross-resistance and usage pertaining to non-clade B infections. 
We will then discuss the evolutionary consequences of ENF treatment and we will 
ﬁ  nish with a summation of these subjects.Therapeutics and Clinical Risk Management 2008:4(2) 434
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Clinical studies
TORO
ENF was approved in 2003 as a salvage therapy agent follow-
ing the success of the Phase III TORO (T-20 vs Optimized 
Regimen Only) clinical trials. TORO 1 (United States, 
Canada, Mexico, and Brazil) and TORO 2 (Australia and 
Europe) assessed the safety and efﬁ  cacy of ENF plus an opti-
mized background (ENF + OB) versus optimized background 
alone (OB) in approximately 1000 treatment-experienced 
patients (n = 663 ENF + OB and n = 334 OB) (Lalezari et al 
2003; Lazzarin et al 2003). Entry criteria for these trials 
included previous treatment with at least one nucleoside 
reverse-transcriptase inhibitor, at least one non-nucleoside 
reverse-transcriptase inhibitor, and at least one (TORO 2) or 
two (TORO 1) protease inhibitors, documented resistance 
to these drugs, or both. After 48 weeks, 30% of the ENF 
+ OB arm had HIV-1 RNA levels 400 copies/mL versus 
12% of the OB alone. The ENF + OB arm also had greater 
decreases in viral load and greater increases in CD4+ T-cell 
counts than OB alone (Nelson et al 2005). The TORO trials 
are also important in that they established the importance of 
using an optimized background as the basis for comparison 
in clinical trials. Based on this evidence, ENF was granted 
accelerated approval by the FDA in 2003.
As part of the long term follow-up for the TORO trials, 
at week 48 patients in the OB arm were required to switch to 
the ENF + OB arm to stay in the study but were allowed to 
switch prior to week 48 if they experienced virologic failure 
(Reynes et al 2007). A total of 230 (68.9%) patients from the 
OB arm switched, of these 222 switched prior to week 48 due 
to virologic failure. These patients along with the original 
ENF + OB arm were followed up to 96 weeks where 114 
(49.6%) of the switch patients and 362 (55%) of the original 
ENF + OB remained on ENF + OB at week 96. At 96 weeks, 
26.5% of patients on ENF + OB had a viral load less than 
400 copies/mL and 17.5% achieved viral suppression below 
50 copies/mL. Patients in the original ENF + OB arm had a 
viral load decrease of 2.1 log10 copies/mL from baseline and 
an increase of 166 CD4+ T-cells. In the switch arm, patients 
had a mean decrease of 1.1 log10 copies/mL from baseline 
and an increase of 116 CD4+ T-cells. The fact that the switch 
patients had a reduced immunologic and virologic response 
compared to patients who started with ENF + OB suggests 
that ENF should be initiated earlier in salvage therapy.
RESIST and POWER
Phase III clinical trial studies RESIST 1 (Randomized Evalu-
ation of Strategic Intervention in multi-drug reSistant patients 
with Tipranivir-North America and Australia) and RESIST 
2 (Europe and Latin America) involved 1509 patients who 
experienced treatment failure with at least two PI-based 
regimens (Hicks et al 2006). All patients in the studies were 
randomized to take ritonavir-boosted tipranivir plus an opti-
mized background (tipranivir/r + OB) or a ritonavir-boosted 
comparator PI plus OB (cPI). After 48 weeks, patients in the 
tipranivir/r + OB group had a greater proportion of respond-
ers (33.6%) versus cPI (15.3%). The treatment response was 
greater in both groups if patients had ENF as part of their OB. 
At 48 weeks, 58.5% of ENF-naïve patients in tipranivir/r + 
OB who received ENF had a treatment response compared 
to 21.6% of ENF-naïve patients in cPI who also received 
ENF. After 96 weeks, 26.4% (197/746) of patients in the tip-
ranivir/r + OB groups had at least a 1 log10 reduction in their 
plasma viremia from baseline, compared to 10.7% (79/737) 
of patients in the cPI group (Gazzard et al 2006). Again, this 
result was more pronounced in patients taking ENF with 
45.2% (56/124) in the tipranivir/r + OB group showing a 
1 log10 reduction in viral load below their pre-RESIST levels, 
compared to 16.5% (16/97) in the cPI group.
The phase III clinical trials POWER 1 (Performance 
of TMC114/r When evaluated in treatment-Experienced 
patients with PI Resistance) and POWER 2 randomized 
highly treatment-experienced patients to ritonavir-boosted 
darunavir plus OB (darunavir/r + OB) or a comparator PI plus 
OB (cPI) (Clotet et al 2007). After 48 weeks, 61% (67/110) 
of patients in the darunavir/r + OB had a reduction in plasma 
viral load of 1 log10copies/mL from baseline versus only 15% 
(18/120) of patients in the cPI group. This result was also 
more pronounced in patients who were ENF-naive. In the 
darunavir/r + OB arm, 81% (29/36) of ENF-naive patients 
taking ENF had a 1 log10 decrease in viral load from baseline 
compared to 56% (34/61) of patients on darunavir/r + OB 
not taking ENF.
The RESIST and POWER studies were similar in terms 
of average age, gender, race, pre-study viral loads and CD4+ 
T-cell counts, prior treatment experience, and evidence of 
drug resistance, however, there are several signiﬁ  cant dif-
ferences (Hill and Moyle 2006). First, the POWER studies 
involved only 255 individuals while the RESIST study 
included 1,509 patients. Second, more people, 23%, in 
POWER used "double-boosted" comparator PIs (two PIs 
combined with ritonavir) compared to 0% in the RESIST 
studies. Third, ENF was more likely to be used in POWER 
than in RESIST trials (47% vs 25%, respectively). After 48 
weeks in both studies, approximately 46% in the darunavir/r 
+ OB POWER groups had viral loads below 50 copies/mL, Therapeutics and Clinical Risk Management 2008:4(2) 435
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compared to 10% in the cPI POWER groups. Conversely, 
in the RESIST studies, 23% of patients in the tipranivir/r 
+ OB groups had viral loads below 50 copies/mL after 48 
weeks, compared to 10% of patients in the cPI groups. In 
the darunavir/r + OB group 81% (29/36) of the ENF-naïve 
patients taking ENF had a viral load reduction of at least 
1 log copies/mL at week 48 versus 58.5% (72/123) of the 
tipranavir/r + OB group. However, it must be noted that in 
the POWER studies, ENF use was stratiﬁ  ed, not randomized, 
and patients receiving ENF were more likely to have higher 
baseline CD4+ T-cell counts, lower baseline viral loads and 
shorter duration of infections. ENF was not randomized or 
stratiﬁ  ed in the RESIST studies and thus interpretations must 
be made with caution when comparing these studies.
Pediatrics
The safety and efﬁ  cacy of ENF has been examined in two 
small open-label studies involving treatment experienced 
children and adolescents (Church et al 2004; Wiznia et al 
2007). As in the TORO studies involving adults, ENF was 
combined with OB therapy consisting of inhibitors of the 
HIV-1 reverse transcriptase and protease enzymes. These 
pediatric patients were followed for periods of up to 96 weeks, 
with frequent evaluation of T cell counts and viral load mea-
surements. Suppression of plasma HIV RNA to undetectable 
levels (50 copies/mL) was uncommon, occurring in about 
10% of participants. However, in the larger study, viral load 
was reduced by a median of 1.17 log10 copies/mL, and the 
median increase in T cell number was more than 100 cells/
mm3 and the CD4 T cell percentage rose by 4.7% (Wiznia 
et al 2007). The treatment responses were greater in children 
than in adolescents, perhaps reﬂ  ecting problems with adher-
ence among the older participants. Although injection site 
reactions were very common in pediatric patients of all ages, 
no patients were forced to discontinue ENF therapy because 
of these or other adverse events.
Clinical management
Dosing
ENF must be administered by subcutaneous injection. ENF 
is in powder form and must be reconstituted with sterile 
water. Standard dosing for adults and adolescents greater 
than 16 years of age or older is 90 mg twice daily. Among 
children, the pharmacokinetics of ENF do not appear to be 
affected by age and children aged 6–16 receive two daily 
doses of 2 mg/kg, not to exceed 90 mg per day (Zhang et al 
2007). ENF is not approved for children less than 6 years of 
age. There are no food restrictions and no known clinically 
signiﬁ  cant interactions between ENF and other medications 
(Boyd et al 2003).
Side effects
ENF is generally well tolerated in both pediatric and adult 
patients (Lalezari et al 2003; Lazzarin et al 2003; Nelson 
et al 2005; Reynes et al 2007). Injection site reactions are 
the most commonly reported side-effect and occur in almost 
all patients. These are typically mild to moderate in severity 
and are rarely treatment-limiting. Other side effects include 
nausea, diarrhea, and fatigue. Eosinophilia has also been 
reported. At 96 weeks in the TORO trials, there were no new 
reported ENF safety issues in adults or children (Reynes 
et al 2007).
Adherence
As noted before, ENF is associated with injection site reac-
tions (ISR) in nearly all patients, including redness, itching, 
pain, and development of nodules at the injection site. These 
ISR represent the most common adverse events associated 
with the agent that when combined with the inconvenient 
route of administration, represent potential barriers to adher-
ence. The inferior treatment responses seen in adolescents 
compared to younger children in one recent trial (Wiznia et al 
2007) may reﬂ  ect problems with adherence (more reports 
of missed doses) seen in the former. Massaging injection 
sites, the use of analgesics, and other simple measures may 
limit ISR and improve adherence (Hu et al 2000; Clotet 
et al 2004).
Clinical usage
A consensus of recommendations concerning the use of ENF 
includes key points regarding resistance testing, initiation 
and discontinuation of therapy, safety concerns, and patient 
education and support is reviewed by Clotet et al (2004). 
The implementation of these recommendations into the day-
to-day clinical practice of providers involved in the care of 
HIV can be critical in improving patient care and compliance 
with ENF therapy.
ENF should be administered in conjunction with an 
optimized background HIV regimen. Resistance testing is 
recommended in patients receiving enfuvirtide in order to 
select an appropriate therapeutic background regimen. To 
this end, genotyping is currently favored as the preferred 
method of resistance testing for patients with chronic HIV 
infection (Clotet et al 2004). Susceptibility testing for ENF 
before initiation is not currently recommended as viruses with 
wild-type HR-1 can vary as much as 500-fold in susceptibility Therapeutics and Clinical Risk Management 2008:4(2) 436
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and these differences were not associated with differences 
in clinical response (Clotet et al 2004, 2007).
ENF is only FDA approved for patients who have failed 
treatment with other agents, and thus is not recommended 
for initial therapy. The best possible initiation time for ENF 
treatment is when the patient can be predicted to have a 
strong, sustained virologic response Treatment with ENF 
is optimized when there are at least two other active agents 
besides ENF in the OB regimen, CD4 T-cell counts are greater 
than 100 and plasma HIV-1 RNA burden is less than 100,000 
copies/mL (Clotet et al 2004). In general, patients who have 
higher CD4 counts, lower viral loads and greater number 
of active agents are more likely to have durable favorable 
virologic and immunologic response to ENF + OB (Lalezari 
et al 2003; Lazzarin et al 2003; Nelson et al 2005; Hicks et al 
2006; Clotet et al 2007; Reynes et al 2007). The fact that 
the TORO switch patients had a reduced immunologic and 
virologic response compared to patients who started with 
ENF+OB reinforces this observation and suggests that ENF 
should be initiated earlier in salvage therapy. Several sub-
studies in addition to the RESIST and POWER studies sug-
gest that not all OB regimens are equal when used with ENF. 
Negredo et al found that patients who received both tenofovir 
and didanosine in their OB had little increase in CD4 counts 
at 8 weeks compared to patients with neither or one of these 
antiretrovirals in their OB regimen (Negredo et al 2005). If 
a boosted PI such as lopinavir/ritonavir (Nelson et al 2005), 
tipranivir/ritonavir (Hicks et al 2006) or duranavir/ritonavir 
(Clotet et al 2007) is the sensitive agent, then a boosted PI 
should be considered in the OB (Youle et al 2006). Patients 
may also initiate ENF in situations where resistance to all 
available treatment options is present, although this is clearly 
a less than optimal approach. Fortunately, additional anti-
retroviral agents, including integrase inhibitors, are nearing 
approval for use that may be combined to create successful 
salvage regimens for patients with advanced disease.
Further concerns with ENF treatment involve safety 
issues of injection site reactions. Good injection technique, 
rotation of injection sites, and massage of the site post-
injection may all aid in reducing the occurrence of injection 
site reactions.
Further recommendations for the management of ENF-
treated patients should include a multidisciplinary approach 
to patient education, training, and support. ENF has high 
viral speciﬁ  city and low toxicity and has been shown to 
achieve a sustained virologic and immunologic response 
in three-class experienced patients. The main drawbacks of 
ENF are the high cost of the drug, the need for parenteral 
administration, and the potential for resistance and viral 
evolution.
Resistance
As with all inhibitors of HIV, variants resistant to ENF have 
been reported. Resistance to ENF usually occurs due to 
mutations in the N-terminal heptad repeat region of gp41 
(HR-1) although mutations in HR-2 have also been reported 
(Rimsky 1998; Roman et al 2003; Cabrera et al 2006; Lu 
2006; Melby et al 2006; Johnson et al 2007; Peuchant et al 
2007). ENF resistance is uncommon in patients who are 
naïve to ENF (Roman et al 2003; Melby et al 2006) where 
the most common polymorphism observed was N42S (16.2% 
of patients). Transmission of ENF resistance has been 
reported in treatment naïve patients (Peuchant et al 2007). 
In vitro studies have shown resistance to ENF conferred by 
mutations in gp41 HR-1 amino acids 36–38 (Rimsky et al 
1998). In vivo resistance associated mutations were seen in 
gp41 amino acids 36–45 within HR-1. In the TORO trials the 
most common mutations (greater than 10% of the viruses) 
were G36D, V38A, V38M, Q40H, and N43D. Lu et al in a 
clonal analysis of serial samples of patients with ENF failure 
found rapid emergence of ENF resistance (Lu et al 2006). At 
week 2 they found mutations at codons 36 (G36E/D/S) and 
38 (V38A/G/M), while at week 4 mutations and codon 40 
(Q40H) and 43 (N43D) were found. In a separate study of 
13 heavily pre-treated patients receiving ENF, mutations in 
HR-1 positions 36, 38, and 43 were found as well as muta-
tions further upstream from HR-1 and in HR-2 (Cabrera 
et al 2006). They observed that mutations at V38E + N42S 
resulted in a 513 fold change in ENF susceptibility while 
mutations at V38A + N42D/T had approximately a 140 fold 
change in ENF susceptibility and N42T + N43K/S resulted in 
a 32–61 fold change in susceptibility. Single mutations V38A, 
G36D, G36S, and N43D conferred a 16-, 8-, 7-, and 18-fold 
change in ENF susceptibility respectively. According to the 
International AIDS Society 2007, mutations associated with 
resistance to ENF include: G36D/S, I37V, V38A/M/E, Q39R, 
Q40H, N42T, N43D (Johnson et al 2007). Furthermore these 
guidelines caution that mutations in HR-2, as well as corecep-
tor usage and density could affect ENF susceptibility.
Cross-resistance
Reeves et al introduced ENF resistance mutations in HR-1 
into both a CCR5 and a CXCR4 utilizing strain to test for viral 
sensitivity to other classes of entry inhibitors (Reeves et al 
2005). They found that ENF-resistance did not confer cross-
resistance to other inhibitors including fusion inhibitors, Therapeutics and Clinical Risk Management 2008:4(2) 437
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chemokine receptor blocking agents, and agents that target 
CD4 binding. Other studies found that clinical resistance to 
ENF did not affect susceptibility to other classes of inhibi-
tors (Fikkert et al 1003; Rimsky et al 1998; Greenberg and 
Cammack 2004; Ray et al 2007).
Coreceptor usage
HIV fusion is a multi-step process that involves conformational 
changes in both gp41 and gp120. Several in vitro studies have 
suggested that ENF susceptibility may be linked to coreceptor 
usage (Derdeyn et al 2000; Reeves et al 2002). However, data 
from a large number of clinical isolates from the TORO trials 
showed that virologic response to ENF was independent of 
baseline coreceptor usage (CCR5, CXCR4, and dual tropic-
viruses) (Melby et al 2006). This study also showed that changes 
in viral load were similar across baseline coreceptor usage.
Non-clade B infection
Although ENF was originally developed based on the gp41 
sequence of clade B, antiviral activity has been shown against 
non-B viral subtypes (Villahermosa et al 2003; Greenberg 
and Cammack 2004; D’Arrigo et al 2007; Holguin et al 
2007). Although there was substantial variability in gp41 
within and between subtypes, primary resistance to enfu-
virtide was rare (Villahermosa et al 2003; D’Arrigo et al 
2007; Holguin et al 2007) in untreated non-B individuals. 
Baseline IC50 values for ENF-naïve individuals were similar 
to other reports for ENF (Holguin et al 2007).
Although ENF has shown susceptibility to non-B strains, 
it is not part of the current WHO approach to treatment guide-
lines for resource-limited settings (Gilks et al 2006). Current 
limitations for ENF in resource-limited settings include cost, 
availability of sterile syringes and water, and availability of 
medical staff to instruct proper injection technique and to 
monitor and treat injection site reactions. However, Brazil, 
the ﬁ  rst developing country to implement policies that provide 
universal access to free antiretrovirals, has included enfuvirtide 
in its treatment guidelines (Nunnet al 2007). Although the cost 
of this drug has been implicated as a major component of the 
doubling Brazil’s total drug expenditures, it should provide 
more treatment options for salvage therapy for patients who 
have limited treatment options (Nunn et al 2007). It remains 
unclear if other developing countries will follow the Brazil 
model and adopt enfuvirtide in their treatment guidelines.
Viral ﬁ  tness and evolution
Understanding the mechanisms by which resistance muta-
tions affect viral ﬁ  tness and evolution, particularly among 
patients with signiﬁ  cant antiretroviral experience is critical 
in determining effective therapy regimens (Deeks et al 2005). 
Viral ﬁ  tness or replication capacity measures the association 
between mutations that confer resistance and changes in 
the ability of the virus to infect cells and reproduce. Fitness 
levels for a given mutation may vary depending on the pres-
ence of other resistance-associated mutations or compensa-
tory mutations as well as other viral characteristics such as 
coreceptor usage and experimental conditions. Viruses that 
harbor mutations at positions 36–45 were found to be less 
virulent than wild-type in the absence of ENF, however in the 
presence of ENF these viruses displayed greater replicative 
ﬁ  tness than wild-type (Lu et al 2004). Although ENF confers 
selective pressure against gp41, the env region must retain 
its resistance against neutralizing antibodies or it will be 
selected against in vivo (Moore and Doms 2003). Reeves et al 
introduced HR-1 mutations that have been shown to confer 
ENF resistance into both CCR5-tropic and CXCR4-tropic 
strains (Reeves et al 2005). They found that these mutations 
reduced infection and fusion efﬁ  cacy, and delayed fusion 
kinetics indicating reduction in viral ﬁ  tness. However, they 
also found that some of these mutations conferred enhanced 
sensitivity to neutralizing monoclonal antibodies, suggesting 
that these mutations may make the virus more susceptible 
to humoral immune responses. Labrosse et al found that 
in 5/6 patients who failed ENF therapy, the emergence of 
resistance mutations did not reduce env replicative capacity 
(Labrosse et al 2006). Further, they found that during ENF 
therapy the dominant env quasi-species differed from the 
dominant quasi-species circulating before ENF was initi-
ated and persisted even after ENF interruption. Deeks et al 
examined the level of continued antiviral activity of ENF in 
the presence of incomplete viral suppression and ENF resis-
tance mutations (Deeks et al 2007). Interruption of ENF only 
while remaining on a stable optimized background regimen 
resulted in a small but signiﬁ  cant increase in plasma viremia 
and a small but signiﬁ  cant decrease in CD4+ T cell counts 
suggesting a modest residual antiviral activity by ENF. ENF 
resistance mutations decreased rapidly during the interrup-
tion and in most patients were undetectable by week 16 in a 
clonal analysis. Kitchen et al examined the viral evolution 
of these clones from 9 of these patients taken at three time 
points: before ENF, during ENF failure and after interrup-
tion of ENF therapy (Kitchen et al 2006). They found strong 
evidence supporting ongoing viral evolution during ENF 
therapy and interruption, suggesting that the loss of ENF 
resistance mutations was due to back-mutation and not recall 
of presumed archive ENF-susceptible strains. This result is Therapeutics and Clinical Risk Management 2008:4(2) 438
Kitchen et al
consistent with the ﬁ  ndings in Labrosse et al (2006). These 
observations that the dominant quasispecies arising during 
ENF therapy persists even after interruption suggests that 
this virus is relatively more ﬁ  t that the presumed archived 
ENF-susceptible virus. This may reﬂ  ect continued evolution 
in env to the host immune system.
Conclusions
ENF is a novel therapeutic agent, and represents the ﬁ  rst 
member of the fusion inhibitor class of antiretroviral agents. 
It represents a valuable choice for treatment-experienced 
patients who otherwise have few options for effective treat-
ment. ENF-resistance has not been shown to confer cross-
resistance to other inhibitors including fusion inhibitors, 
coreceptor inhibitors, and agents that target CD4 binding. 
ENF has been successfully used to produce durable reduc-
tions in viremia even in patients with multi-drug resistance. 
The likelihood of a sustainable virologic and immunologic 
responses is maximized when the patient has at least 2 
other active agents besides ENF in the OB, CD4 counts are 
greater than 100 cells/mm3, and plasma viral burden is less 
than 100,000 copies/ml. Based on the results from several 
clinical trials, this likelihood may be even greater when used 
with an active boosted PI regimen. The differing results from 
in vivo and in vitro tests of viral ﬁ  tness of ENF mutations 
along with the ﬁ  nding of continued evolution of env during 
ENF treatment and interruption suggests that there exists a 
stronger selective pressure, perhaps the immune system, that 
is driving the evolution of the virus forward. This, coupled 
with the high cost and inconvenience of parental administra-
tion of ENF, and the limited residual antiviral activity may 
limit the long-term use of the drug in patients who have 
ENF-resistance. Fortunately, with the introduction of new 
novel antiretroviral agents, including integrase inhibitors, 
that are nearing approval for use, options for the treatment 
of patients with multi-class resistant HIV-1 are improving. 
Overall, ENF treatment has been proven effective among 
treatment-experienced individuals infected with HIV-1.
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